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1. Introduction  
In the early to mid 1970’s, hallmark studies were published demonstrating the ability to 
isolate and derive adult fibroblast cell colonies from the bone marrow stroma and the spleen 
(Friedenstein et al., 1970; Friedenstein and Kuralesova, 1971). These fibroblast-like cells, later 
termed bone marrow stromal cells (BMSCs) or bone marrow-derived mesenchymal stem 
cells (MSCs), were shown to proliferate in culture, to continually grow upon passaging 
while maintaining stable karyotypic characteristics, and were comprised of cells that had 
multipotent potential to differentiate along multiple mesenchymal cell lineages such as 
bone, cartilage, fat and could support hematopoietic stem cell (HSC) differentiation (Bab et 
al., 1984; Bab et al., 1986; Friedenstein et al., 1970; Friedenstein et al., 1974b). Numerous 
studies spurred from these findings, which also led researchers in this area to explore the  
functions of these cells in vitro and in their normal microenvironment. Bone marrow 
stromal cells were transplanted in vivo to determine if they had the ability to re-establish the 
marrow microenvironment, and it was reported that the ex vivo expanded stromal cells did 
indeed restore the hematopoietic niche within the bone marrow (Friedenstein et al., 1974a). 
These experiments further developed the hypothesis that within the bone marrow stroma 
resided a heterogeneous mixture of cells that function as a repository of progenitors, known 
as MSCs, that may migrate out of their stem cell niche in response to disease, injury, and 
aging. Therefore, extensive investigation into the identification of MSCs and their utility for 
cell-replacement therapies were the basis for a new emerging field known as tissue 
engineering (Ashton et al., 1980; Bab et al., 1986; Owen and Friedenstein, 1988; Beresford, 
1989; Jaiswal et al., 1997; Krebsbach et al., 1999). 
In the 1980’s and 1990’s, many groups further demonstrated that culture-adherent MSCs 
present in the marrow stroma were capable of differentiation into bone, cartilage, muscle, 
tendon, and fat for multiple species such as canine, chicken, rabbit, rat, and mouse (Jaiswal 
et al., 1997). Using the expertise gained from these culture systems, MSCs were then isolated 
and propagated from human adult bone marrow (hMSCs) (Bab et al., 1988); (Krebsbach et 
al., 1997). Human MSCs were then used with site-specific delivery vehicles to repair bone, 
cartilage, and other connective tissues (Haynesworth et al., 1992a; Haynesworth et al., 
1992b). Additionally, a series of monoclonal antibodies were developed to identify 
characteristic surface markers on hMSCs, which would prove to be beneficial to researchers 
interested in not only identifying MSCs, but also subpopulations of osteoprogenitor cells 
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(Haynesworth et al., 1992a; Haynesworth et al., 1992b); (Gronthos et al., 1999). 
Simultaneously, Caplan et al. used the embryonic chick limb bud mesechymal cell culture 
system as an assay for the purification of inductive factors in bone to further develop the 
technology for isolating, expanding, and preserving the stem cell capacity of adult human 
bone marrow-derived mesenchymal stem cells (Caplan, 2005). With this newly acquired 
knowledge and the emerging technologies in biomedical engineering, hMSCs became the 
principle cell source for cell-based pre-clinical bone tissue engineering studies.  
Currently, substantial advances have been made to address clinical needs for regeneration 
of damaged or diseased tissues. The three main approaches of cell-based clinical therapies 
that employ the use of hMSCs are: 1) from a tissue engineering standpoint where cells are 
incorporated into 3D biomaterial scaffolds for the replacement of tissue in vivo, 2) from a cell 
replacement therapy standpoint where allogeneic donor cells are used to replace ablated 
tumors and diseased cells; and 3) from a inductive standpoint where cells provide cytokine 
and growth factor cues that stimulate host reparative events and inhibit degenerative events 
(Caplan, 2005). Thus, clinical protocols were developed to establish that autologous hMSCs 
could be safely implanted back in order to reconstitute the marrow microenvironment for 
breast cancer and osteogenesis imperfecta (OI) patients following chemotherapy treatment 
(Koc et al., 2000; Horwitz et al., 2002). Additionally, hMSCs have been shown to have 
immunomodulatory effects and could induce immune suppression in patients (Le Blanc and 
Pittenger, 2005); (Aggarwal and Pittenger, 2005). Although the use of hMSCs has been 
successfully used in some cases, there are challenges that scientists and clinicians must 
overcome before the transplantation of these cells is incorporated into routine clinical 
practice. Specifically, the classic method to isolate MSCs from bone marrow relies on their 
capacity to adhere to plastic, their resistance to trypsinization during passaging, and 
proliferation in growth medium containing serum (Olivier et al., 2006). However, cell 
availability is greatly limited with this method because MSCs are present at low 
concentrations in the marrow, occurring at less than 1 in 100,000-500,000 nucleated cells 
(Caplan, 2005). Also, the availability of tissues for their isolation remains limiting and 
requires invasive procedures that may cause severe donor site morbidity.  
Therefore, an alternative source for generating MSCs can be found in human embryonic 
stem cells (hESCs) (Thomson et al., 1998). Human ESCs are an alternative source for 
generating MSCs due to the fact that they can theoretically be expanded infinitely and also 
because using these cells would eliminate the need for invasive cell harvesting techniques. 
Host immune rejection could also be circumvented by the use of autologous hESCs 
generated from nuclear transfer or from immune compatible allogeneic hESCs.  Derivation 
of mesenchymal stem cells from human ES cells will further the understanding of the 
differentiation pathways and important cellular events that occur during early human 
development and could also have useful clinical applications. Because of the therapeutic 
potential, particularly in the areas of cell therapy and regenerative medicine, derivation of 
MSCs from hESCs (hESC-MSCs) has specific advantages over the current “gold standard” use 
of autologous and allogeneic adult hMSCs for bone tissue engineering. (Olivier et al., 2006).  
2. Human embryonic stem cells 
The major advancements in the area of stem cell culture, derivation, propagation, and 
differentiation paved the way for a pivotal discovery that was reported in a 1998 study from 
the University of Wisconsin. Thomson et. al. described the first successful isolation and long 
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term sustained culture of a small cluster cells from the inner cell mass of four-day old embryos 
(Thomson et al., 1998). These cells, known as human embryonic stem cells (hESCs), represent a 
robust biologic tool and model system through which the scientific and medical communities 
will better understand human development, disease pathophysiology, organogenesis, and 
mechanisms for cellular differentiation; all of which will help develop and improve the field of 
regenerative medicine. These embryonic stem cells are derived by the selection and expansion 
of individual colonies rather than clonal expansion of a single cell. Human ESCs are 
pluripotent cells that are presumed to have virtually unlimited proliferation capacity in vitro, 
maintain normal karyotypic characteristics, sustain high levels of telomerase activity, and 
retain uniform undifferentiated morphology in prolonged culture (Thomson et al., 1998). In 
addition, hESCs have the ability to differentiate along the three embryonic germ layers in vivo 
as evidenced by teratoma formation after injection into severe combined immunodeficient 
(SCID) mice. The teratomas can contain gut epithelium (endoderm); cartilage, bone, smooth 
muscle, and striated muscle (mesoderm); and neural epithelium, embryonic ganglia, and 
stratified squamous epithelium (ectoderm). They have also been shown to express certain cell 
surface markers that are widely used to confirm pluripotency, such as stage-specific 
embryonic antigen SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. Oct-4, a 
transcription factor, has been identified as another key indicator of the undifferentiated state.   
To maintain their self renewal capacity, hESCs were originally cultured on mouse 
embryonic fibroblast (MEF) feeder layers and grown under serum-free conditions using 
serum replacement (SR) with supplements of basic fibroblast growth factor (bFGF). Under 
these culture conditions, hESCs have been passaged continuously and maintained 
pluripotency as well as a normal karyotype. However, it has been reported that hESCs have 
been successfully cultured with feeder cells of human origin, such as human bone marrow 
stromal cells (hBMSCs), human placental fibroblasts, human foreskin fibrobalsts (hFFs), 
feeders derived from hESCs, and on polymeric substrates in feeder free conditions (Cheng et 
al., 2003; Genbacev et al., 2005; Wang et al., 2005; Stojkovic et al., 2005; Hovatta et al., 2003; 
Villa-Diaz et al., 2010). In order to safely use hESCs in a clinical setting, it is imperative that 
that feeder-free and animal product-free culture conditions are explored further to 
overcome the risks of cross-transfer of pathogens from xenogeneic sources.  
The ability of hESCs to maintain an undifferentiated state indefinitely in culture and to 
differentiate into all cell types and tissues within the human body has created a high 
demand for research. Although the cells are of great scientific interest, progression of this 
type of research has been met with great controversy and resistance due to the ethical 
concern of destroying early human embryos for derivation of hESC lines (Knowles, 2004; 
Baschetti, 2005; Gruen and Grabel, 2006).  Nevertheless, once the ethical concerns are abated 
through placement of the appropriate guidelines and policies on research, the hESC field 
will not only evolve, but will continue to rapidly progress toward monumental medical and 
scientific breakthroughs.  
3. Human embryonic stem cell derived mesenchymal stem cells 
The current major goal for hESC research in regenerative medicine is the controlled 
differentiation into specific progenitor cells for the purpose of replacing or regenerating 
damaged tissue. Therefore, the ability to obtain large quantities of multipotent cells from 
hESCs represents a challenge for cell based therapy and tissue engineering strategies that 
currently rely on human bone marrow stromal cells (hMSCs). Within the diverse population 
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of hMSCs, there exist early progenitor mesenchymal stem cells capable of self-renewal and 
multi-lineage differentiation into cell types such as osteoblasts, chondrocytes, and 
adipocytes (Bianco et al., 2003; Wagers and Weissman, 2004). While hMSCs make a useful 
source of osteoprogenitor cells for tissue engineering strategies, they have limited 
proliferation and differentiation capacity.  In contrast, hESCs which are able to proliferate 
indefinitely in vitro, represent a potentially unlimited source of mesenchymal stem cells.   
Recent studies demonstrate that the derivation of hESC-MSCS, mesenchymal precursors 
derived from hESCs, has been achieved via various isolation methods, and the generation of 
osteoblasts has been achieved in co-culture with primary bone derived cells (PBDs), in the 
presence of known osteogenic supplements, and in transwell co-culture with hBMSCs (Ahn 
et al., 2006; Cao et al., 2005; Duplomb, 2007; Karner et al., 2007; Karp et al., 2006; Sotille et al., 
2003; Tong et al., 2007). Although the identification and characterization of hESC-MSCs has 
been reported, the data are quite vast and varied in terms of the derivation method, cell 
culture conditions, the mechanism of differentiation (epithelial-mesenchymal transition vs 
neural crest stem cell-mesenchymal differentiation), multilineage differentiation potential, 
and surface markers used to select for a pure mesenchymal stem cell subpopulation. As the 
field continues to evolve, careful attention should be placed on standardizing these 
parameters along clinical-grade good manufacturing practice (GMP guidelines). Through 
the isolation and identification of hESC-MSCs and the ability to produce a large supply of 
progenitor cells that can be genetically modified, the field hESC-MSC based tissue 
engineering and regenerative medicine strategies holds great promise. 
3.1 Derivation methods 
Thorough and extensive investigation into the definition, differentiation, and identification 
of mesenchymal stem cells has occurred over the last three decades. However, there are 
fundamental mechanistic and developmental concepts that remain poorly understood. The 
foundation laid by pioneers in the MSC field has provided current researchers with a 
breadth of knowledge to draw upon because the same fundamental questions are being 
investigated to identify the true ’’MSC“ from differentiating hESCs. Many investigators state 
that although MSCs isolated from the adult bone marrow have been shown to differentiate 
in vitro and in vivo, as well as have been successfully used in a clinical setting to repopulate 
the marrow environment in cancer patients, harvesting and utilizing adult hMSCs has 
disadvantages such as tissue availability, donor site morbidity, and host immune rejection 
(Caplan, 2005; Horwitz et al., 2002; Karp et al., 2006). Therefore, hESCs have been the topic of 
great discussion and interest as a potential repository of cells that can provide an unlimited 
number of specialized mesenchymal stem cells known as hESC-MSCs. 
Numerous isolation protocols have been reported describing successful derivation and 
differentiation of hESC-MSCs (Arpornmaeklong et al., 2009; Barberi et al., 2005; Brown et al., 
2009; de Peppo et al., 2010a; de Peppo et al., 2010b; Evseenko et al., 2010; Karlsson et al., 2009; 
Karp et al., 2006; Kopher et al., 2010; Kuznetsov et al., ; Lian et al., 2007; Olivier et al., 2006; 
Smith et al., 2009; Trivedi and Hematti, 2007; Xu et al., 2004). One of the first reports of the 
derivation of a MSC-like progenitor population was in 2004, where fibroblast-like hESC 
derivatives were infected with a human telomerase reverse transcriptase (hTERT) 
retrovirus, as a result showed extended proliferative capacity, supported undifferentiated 
growth of hESCs as a feeder layer, and differentiated into osteoblasts (Xu et al., 2004). 
Following that study, another group reported the successful production of hESC-MSCs 
when cultured on murine OP9 stromal cells in the presence of heat-inactivated FBS, and 
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indicated that the hESC-MSCs had a similar immunophenotype to hMSCs after flow 
cytometry was performed to purify the hESC-MSC population from the stromal cell feeder 
(Barberi et al., 2005). Another method for hESC-MSC production involved the use of 
spontaneously differentiated hESC colonies. The cells obtained became morphologically 
fibroblastic and homogenous after multiple passages, possessed a characteristic MSC 
immunophenotype, and supported hESC and hematopoietic progenitor cell growth (Olivier 
et al., 2006). Of particular importance, two reports showed the ability to reproducibly derive 
clinically compliant hESC-MSCs in a xeno-free environment where all contaminating 
animal-derived components were replaced with human-derived or recombinant 
components. Thus, they cultivated a hESC-MSC line suitable for clinical use ((Karlsson et al., 
2009; Lian et al., 2007). Other groups described similar findings, demonstrating that hESCs 
had the ability to reproducibly proliferate, differentiate, and commit to the mesodermal 
lineage in various cell culture conditions (both in monolayer and 3D) while retaining their 
multilineage differentiation potential and self renewal capacity, further demonstrating their 
high potential for tissue engineering applications (Arpornmaeklong et al., 2009; Brown et al., 
2009; de Peppo et al., 2010a; de Peppo et al., 2010b; Evseenko et al., 2010; Kopher et al., 2010; 
Lian et al., 2007; Smith et al., 2009; Trivedi and Hematti, 2007). 
In summary, multiple approaches have attempted to achieve the most direct and efficient 
derivation of hESC-MSCs. A variety of studies have compared using the embryoid body 
(EB) step versus omitting this step, using multiple media formulations with and without 
serum, and using feeder-free cultures versus co-culture. These reports greatly contributed to 
the field, however, a concensus on the most appropriate method of isolation and culture is 
absolutely necessary to make hESC-MSC based therapies in a clinical setting a reality. 
3.2 Osteoprogenitor cell differentiation from hESCs 
Currently, there are major gaps in the knowledge about the growth factors and three-
dimensional milieu that influence and direct osteoblast differentiation. The generation of 
osteoprogenitors from hESC-MSCs has been shown to be successful as evidenced by 
osteogenic gene expression of runt-related transcription factor 2 (Runx2), collagen type 1A 
(Col1A1), bone-specific alkaline phosphatase (ALP),  and osteocalcin (OCN); mineralized 
matrix confirmed by von Kossa and Alizarin Red staining; bone nodule formation in vitro; 
and bone formation in vivo in diffusion chambers and transplants to orthotopic sites  
(Duplomb, 2007). One of the first differentiation studies used cultured hESCs in the presence 
of defined osteogenic supplements for 21 days, and was able to demonstrate mineralization 
and induction of osteoblastic marker expression (Sotille et al., 2003). Human ESCs have been 
co-cultured with primary bone derived cells (PBDs) to induce osteoblast differentiation 
without the addition of exogenous factors, and cultured in vitro in the presence of known 
osteogenic factors without the embryoid body (EB) formation step – both studies confirming 
that hESCs have the capacity to differentiate into osteoblasts (Ahn et al., 2006; Karp et al., 
2006). Whereas, other findings suggest that 12 day EB-derived hESC-MSCs are equally 
capable of undergoing multilineage differentiation in vitro (Cao et al., 2005).  It has also been 
shown that hESC-MSCs can not only differentiate into functional osteoblasts and adipocytes 
and express markers characteristic of hMSCs, but they can also be successfullly transduced 
with an osteogenic lineage specific Col2.3-GFP lentivirus in order to track and isolate cells as 
they underwent differentiation. The transgene construct used has been shown to be a useful 
tool for studying hBMSC differentiation (Brown et al., 2009). When the hESC-MSCs began as 
pre-osteoblasts there was low GFP expression, however,  increased GFP expression was 
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detected after 28 days culture in osteogenic medium, suggesting that hES-MSCs 
differentiated into mature osteoblasts. The ability to track differentiation allowed the 
isolation of osteoprogenitor cells from the derived hESC-MSC population. These studies 
suggest that in particular, the osteoprogenitor populations derived from hESCs have 
tremendous potential, and can serve as a tool through which we can characterize early bone 
development and cellular behavior on bone-related biomaterials.  
3.3 Gene transcription and proteomic array analyses 
The therapeutic capacity of hESC-MSCs to treat a variety of diseases lies within their 
capability to different into numerous cell phenotypes to repair or regenerate tissues and 
organs. However, it remains to be determined if transplanted MSCs, whether of hESC or 
adult stem cell origin, contribute to and integrate within the majority of newly formed 
tissue, or perhaps via paracrine action mediate and stimulate host repair and regeneration. 
To that end, investigation into the therapeutic potential of the hESC-MSC paracrine 
proteome has been conducted.  Within the study, defined serum-free culture medium was 
conditioned by hESC-MSCs and subsequently analyzed via multidimensional protein 
identification and cytokine antibody array analysis (Sze et al., 2007). The array data revealed 
over 200 unique gene products that play a role in biological processes such as metabolism, 
defense, response, and tissue differentiation including vascularization, hematopoiesis, and 
skeletal development. These processes and pathways are associated with numerous cellular 
processes that are activated to participate in injury, repair, and regeneration, as well as to 
facilitate immune cell migration to the site of injury, ECM remodeling, and increases in 
cellular metabolism (Sze et al., 2007). The identification of a large number of MSC secretory 
products that can act as paracrine modulators provides insight into the potential mechanism 
of action by which hESC-MSCs may participate in tissue repair and disease treatment.  
Another study investigated the gene expression profile of differentiating hESC-MSCs and 
reported that during derivation major transcriptional changes occurred, resulting in an 
expression profile very similar to that of hMSCs (de Peppo et al., 2010b). The major 
questions addressed were how the transcriptome may be affected by the hESC-MSC 
derivation process and whether hESCs and their MSC derivatives were distinct or 
equivalent to one another. The findings in the hESC-MSC population revealed a down-
regulation in pluripotency genes such as the OCT family of genes, NANOG, TDGF1, LIN28, 
GDF3, and ZIC3, down regulation in tumor development p53-associated genes LTBP2 and 
TFAP2A, up-regulation of mesodermal lineage commitment genes such as RUNX2, TGBR2, 
BMPR2, and TFAP2A, and up-regulation of genes supportive of craniofacial development 
and osteogenesis such as DLX1, DLX2, and MSX1. Lastly, and importantly, the immunological 
profile of hESC-MSCs displayed lower expression than hMSCs of HLA-ABC and HLA-DR, 
two markers characteristic of the inflammatory immune response. These findings suggest that 
the hESC-MSCs may be more immuno-privileged than hMSCs, thus another piece of evidence 
supporting the notion that hESC-MSCs represent a suitable alternative for cell transplantation 
therapies (Romieu-Mourez et al., 2007; de Peppo et al., 2010a). 
3.4 Epithelial-mesenchymal transition 
Cells within the body are derived from a single cell, with variations of cell phenotypes 
resulting from expression of a specific and defined transcriptome, thus further imparting 
diversity in cellular signaling and function. Epithelia are considered to be highly plastic 
during embryogenesis and have the ability to shuttle back and forth between mesenchyme 
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and epithelia through the process know as epithelial-mesenchymal transition (EMT). It is 
one mechanism that gives rise to mesenchymal-like behavior to cells in numerous different 
settings (Kalluri, 2009). Historically, it has been proposed that epithelial cells have to be 
terminally differentiated to in order to perform defined functions involved in organ 
development. However, experimental evidence has suggested that epithelial cells can alter 
their phenotype based on the influence of microenvironment (Boyer et al., 2000). Therefore, 
EMT has been accepted as a mechanism by which fibroblasts and mesenchymal cells are 
formed in injured tissues. In the adult, the process of EMT occurs during tissue regeneration 
and wound healing by facilitating mesenchymal cell migration to invade surrounding 
tissues. This was described as one of the three EMT subtypes that occurs, and is also 
suggested to be an underlying mechanism for derivation of hESC-MSCs (Zeisberg and 
Neilson, 2009; Ullmann et al., 2007).  
It has been reported that hESCs grown in monolayer in feeder-free conditions, without 
MEFs or other supporting cells, form uniform sheets of epithelial cells after removal from 
standard feeder culture systems (Boyd et al., 2009; Ullmann et al., 2007). The uniform 
epithelial sheets exhibit characteristic mesodermal gene expression patterns that appear to 
undergo EMT that results in a highly proliferative population of cells that over time become 
uniformly homogenous with a mesenchymal stem cell morphology. It is in fact these 
homogenous cells that many researchers identify as hESC-MSCs, which have the ability to 
differentiate along multiple mesenchymal cell lineages in vitro. More specifically, these 
studies find that the hESCs that underwent mesenchymal differentation in monolayer 
culture were over 80% positive for E-cadherin, a characteristic epithelium marker, and 
maintained expression while cell morphology changed. Additionally, the cells that were 
undergoing apparent EMT were positive for the characteristic markers such as CD73, CD90, 
CD 105 and CD166, and negative for CD31, CD34, CD45, CD133 and CD146, further 
confirming the formation of a mesenchymal progenitor cell population (Boyd et al., 2009). 
The key significance of these studies is the finding that hESCs are behaving in culture in a 
manner similar to that of normal embryogenesis, thus underscoring the importance of using 
hESCs as a tool for better understanding overall human development. 
3.5 Tissue engineering strategies for human clinical applications 
A major challenge for using stem cells in a clinical setting is the need to identify an ideal 
stem cell candidate that is multipotent while retaining its self-renewal capacity. Although 
hMSCs make a useful source of progenitor cells for tissue engineering strategies, as 
evidenced by their multipotent potential and immunosuppressive characteristics, their 
limited proliferative and differentiation capacity represent an obstacle for therapeutic 
application. In contrast, hESCs with their ability to proliferate indefinitely in vitro and multi 
lineage differentiation capacity represent an unlimited source of progenitor cells, 
specifically, mesenchymal progenitor cells.   Therefore, it is necessary to establish clinical-
grade GMP protocols for the derivation, identification, and isolation of hES-MSCs, to 
produce large quantities of genotypically homogenous progenitor cells that can be modified, 
and to fully characterize these cells for tissue regeneration strategies. Tissue engineering is 
an emerging field of research aimed at regenerating functional tissues by combining cells 
with a supporting substrate or biomaterial that possesses design characteristics that deliver 
progenitor cells and important signalling molecules in a spatially and temporally controlled 
manner, while promoting vascularization and tissue invastion into the interior of the 
scaffold.  Ideally, biomimetic scaffolds designed for hESC-MSC based tissue engineering 
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strategies would contain inductive signaling cues for proliferation and differentiation, 
possess composite material properties that conferred the ability to generate multi-layered 
hybrid tissues, and have tunable three-dimensional geometrical architecture that 
appropriately restores form and function to anatomical defects or diseased tissues.  
Within the hESC field, the use of 3D scaffolds has been employed in only a few reports 
(Arpornmaeklong et al., 2009; Ferreira et al., 2007; Kaufman et al., 2010; Levenberg et al., 2003; 
Kim et al., 2007; Kuznetsov et al., 2010; Smith et al., 2009). Investigators have used collagen 
scaffolds for hepatocye differentiation, and porous polylactic/polyglycolic biomaterial 
sponges  to direct neural, chondrogenic, or hepatocytic lineages (Levenberg et al., 2003).  
While other studies have shown that 3D porous alginate scaffolds to provide a conducive 
environment for generation of well-vascularized embryoid body derived hESCs (Ferreira et 
al., 2007).  Within the bone tissue engineering field, the use of architecturally designed 
scaffolds with hESC-MSCs is seen even less frequently. It has been reported that hESC-
MSCs were capable of forming bone tissue in vivo when implanted subcutaneously after 8 
weeks in the presence of BMP-2 (Kim et al., 2007). In 2009, Arpornmaeklong et al. reported 
the influence of composite collagen scaffolds on the osteogenic differentiation of hESC-MSCs 
in vitro as indicated by osteogenic gene induction, increased ALP activity, and the presence of 
mature bone ECM proteins; all of which are characteristic of the osteoblast phenotype. From 
an in vivo standpoint, enriched osteoprogenitor cells were encaspulated in fibrin gels mixed 
with ceramic particles and implanted in a rat calvarial defect model. After six weeks, the 
identification of transplanted hESC-MSCs in newly formed bone verified the role that MSCs 
derived from hESCs played in the bone regeneration process (Arpornmaeklong et al., 2009). 
Another study demonstrated that hESC-MSCs can form mineralized tissue  in vitro when 
cultured on 3D nanofibrous polylactic acid (PLLA) in the presence of BMP-7, illustrating the 
capability of hESC-MSCs to differentiate in 3D culture for bone regeneration purposes (Smith 
et al., 2009). Most recently, a comprehensive study investigated multiple media formulations 
and cell culture conditions for efficient derivation of a homogenous hESC-MSC population. To 
determine their in vivo osteogenic potential, cells were implanted up to 16 wks with biphasic 
ceramic particles and histology revealed cells of human origin were embedded with the bone, 
including broad areas of multiple intertwining trabeculae (Kuznetsov et al., 2010). 
It is hypothesized that the hESC-MSCs not only require a 3D biomaterial, but also inductive 
cues. This suggests that for tissue formation, hESCs may require additional biological cues 
such as pro-osteogenic factors for attachment, proliferation, and directed differentiation on 
biomaterials. For bone formation specifically, hESCs may require an osteoconductive 
biomaterial with not only the appropriate scaffold architecture, but one that also can 
associate cellular and molecular elements to increase cellular response to the biomaterial. 
4. Conclusion 
Human ESC research is a rapidly developing field, and has the potential to impact the 
medical and scientific community immensely. It is vitally important that we continue to 
explore hESC biology in order to realize the potential of hESCs to cure diseases. The 
derivation of mesenchymal stem cells from human embryonic stem cells is an area of active 
investigation in that hESC-MSCs potentially offer insight into embryonic mesodermal 
development events, as well as provide information about underlying differentiation 
mechanisms and signaling pathways that have been unclear heretofor. In addition to 
elucidating the mechanisms by which hESC-MSCs differentiate, it is equally important to 
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better understand how the 3D biomaterial microenvironment can be manipulated to direct 
and control this process. In general, stem cell research advances the knowledge and 
understanding of how an organism develops and how progenitor cells migrate from the 
stem cell niche to the site of damaged or diseased tissue. To improve upon the overall 
quality of human health, scientists must continue to work collaboratively with clinicians to 
drive translational “bench-to-bedside” research. To this end, extensive investigation into the 
xeno-free derivation, robustness, and non-tumorigenic safety of hESC-MSCs will be 
absolutely necessary as the field progresses toward the realization of clinical tissue 
engineering and regenerative medicine therapies. 
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